To determine if apixaban is superior to aspirin for the prevention of recurrent stroke in patients with cryptogenic ischemic stroke and atrial cardiopathy, and to determine if the relative efficacy of apixaban over aspirin increases with the severity of atrial cardiopathy.
The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death.
To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke or death from any cause in patients with recent ICH and atrial fibrillation. Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
The overall goal of the DISCOVERY study is to better understand what factors contribute to changes in cognitive (i.e., thinking and memory) abilities in patients who experienced a stroke. The purpose of the study is to help doctors identify patients at risk for dementia (decline in memory, thinking and other mental abilities that significantly affects daily functioning) after their stroke so that future treatments may be developed to improve outcomes in stroke patients.
VERIFY will validate biomarkers of upper extremity (UE) motor outcome in the acute ischemic stroke window for immediate use in clinical trials, and explore these biomarkers in acute intracerebral hemorrhage.
The primary goals of this study are to determine whether treatment of obstructive sleep apnea (OSA) with positive airway pressure starting shortly after acute ischemic stroke or high risk TIA (1) reduces recurrent stroke, acute coronary syndrome, and all-cause mortality during 6 months after the event, and (2) improves stroke outcomes at 3 months in patients who experienced an ischemic stroke.
This study focuses on individuals who have had a brain hemorrhage and were taking a statin drug. The purpose of the study is to determine whether it is better to continue or discontinue statin drugs in patients who had a brain hemorrhage while taking a statin drug.
CREST-2 is designed to compare three different methods of stroke prevention to find the safest and most effective treatment: intensive medical management alone compared to intensive medical management in combination with carotid enarterectomy and carotid stenting.
